Earlier today, Biogen Inc BIIB agreed to acquire Reata Pharmaceuticals Inc RETA for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3 billion. William Blair analysts ...
In the past decade, pontoon boats have evolved from slow-moving, floating-lawn-chair platforms to cruising living rooms with unique and exciting fishing and watersports capabilities. Ranger’s new ...
Citi analysts Yigal Nochomovitz, Steven Seedhouse and Yang Huang believe Reata Pharmaceuticals, Inc. RETA has considerable room to operate in the $5 billion Pulmonary Arterial Hypertension (PAH) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback